T1	Participants 25 82	participants with depression and impaired quality of life
T2	Participants 273 313	patients with reduced ejection fraction.
T3	Participants 472 536	participants with heart failure with preserved ejection fraction
T4	Participants 733 1081	patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients completed the Kansas City Cardiomyopathy Questionnaire, 3395 patients completed European QOL 5D Visual Analog Scale, and 1431 patients in United States and Canada completed the Patient Health Questionnaire-9.
T5	Participants 1996 2233	Patients with heart failure with preserved ejection fraction, who were younger had higher New York Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eastern Europe or were taking hypoglycemic agents
T6	Participants 2260 2288	impaired QOL and depression.
